Latest Insider Transactions at Chinook Therapeutics, Inc. (KDNY)
This section provides a real-time view of insider transactions for Chinook Therapeutics, Inc. (KDNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CHINOOK THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CHINOOK THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2022
|
Davis Jerel Director |
SELL
Open market or private sale
|
Indirect |
1,000,000
-14.23%
|
$16,000,000
$16.0 P/Share
|
|
Jan 03
2022
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,000
-14.23%
|
$6,400,000
$16.0 P/Share
|
|
Jan 03
2022
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
600,000
-14.21%
|
$9,600,000
$16.0 P/Share
|
|
Dec 23
2021
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+18.13%
|
$0
$0.35 P/Share
|
|
Dec 01
2021
|
Eric Bjerkholt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,750
-21.77%
|
$92,000
$16.02 P/Share
|
|
Dec 01
2021
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,414
+38.33%
|
-
|
|
Nov 15
2021
|
Srinivas Akkaraju Director |
BUY
Open market or private purchase
|
Indirect |
1,215,000
+20.92%
|
$17,010,000
$14.0 P/Share
|
|
Nov 10
2021
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,230
-4.42%
|
$93,450
$15.48 P/Share
|
|
Nov 09
2021
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-54.98%
|
$65,000
$13.53 P/Share
|
|
Nov 09
2021
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+21.56%
|
$0
$0.35 P/Share
|
|
Nov 08
2021
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,770
-8.91%
|
$206,550
$15.17 P/Share
|
|
Nov 05
2021
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,000
-5.86%
|
$280,000
$14.0 P/Share
|
|
Nov 05
2021
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+7.91%
|
$0
$0.42 P/Share
|
|
Oct 21
2021
|
William Mariner Greenman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,663
+7.18%
|
$3,326
$2.6 P/Share
|
|
Oct 06
2021
|
Alan Glicklich Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,489
-35.04%
|
$29,868
$12.37 P/Share
|
|
Oct 06
2021
|
Alan Glicklich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,103
+50.0%
|
-
|
|
Oct 06
2021
|
Andrew James King Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,557
-35.04%
|
$42,684
$12.37 P/Share
|
|
Oct 06
2021
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,151
+50.0%
|
-
|
|
Oct 06
2021
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,796
+17.96%
|
-
|
|
Oct 06
2021
|
Tom Frohlich Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,359
-4.41%
|
$88,308
$12.37 P/Share
|
|
Oct 06
2021
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,580
+7.52%
|
-
|
|
Sep 24
2021
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.53%
|
$0
$0.42 P/Share
|
|
Sep 24
2021
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,000
-13.04%
|
$260,000
$13.0 P/Share
|
|
Sep 20
2021
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+1.79%
|
$24,000
$12.0 P/Share
|
|
Aug 27
2021
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
340,000
-10.79%
|
$4,760,000
$14.0 P/Share
|
|
Aug 27
2021
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
510,000
-10.78%
|
$7,140,000
$14.0 P/Share
|
|
Aug 27
2021
|
Davis Jerel Director |
SELL
Open market or private sale
|
Indirect |
850,000
-10.78%
|
$11,900,000
$14.0 P/Share
|
|
Aug 19
2021
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+2.71%
|
$36,000
$12.0 P/Share
|
|
Aug 18
2021
|
Srinivas Akkaraju Director |
BUY
Open market or private purchase
|
Indirect |
208,500
+5.82%
|
$2,293,500
$11.98 P/Share
|
|
Aug 18
2021
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
7,000
+6.26%
|
$77,000
$11.74 P/Share
|
|
Jun 16
2021
|
Alan Glicklich Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-100.0%
|
$320,000
$16.35 P/Share
|
|
Jun 16
2021
|
Alan Glicklich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$0
$0.42 P/Share
|
|
Jun 14
2021
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.97%
|
$0
$0.35 P/Share
|
|
May 14
2021
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+1.27%
|
$14,000
$14.44 P/Share
|
|
Dec 21
2020
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+20.65%
|
$0
$0.35 P/Share
|
|
Dec 09
2020
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+3.4%
|
$26,000
$13.07 P/Share
|
|
Dec 08
2020
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+3.52%
|
$26,000
$13.24 P/Share
|
|
Nov 23
2020
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
929
+1.73%
|
$12,077
$13.67 P/Share
|
|
Nov 20
2020
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
571
+1.09%
|
$7,423
$13.69 P/Share
|
|
Nov 19
2020
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.96%
|
$6,500
$13.5 P/Share
|
|
Nov 11
2020
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+4.69%
|
$32,500
$13.75 P/Share
|
|
Nov 10
2020
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+3.97%
|
$26,000
$13.86 P/Share
|
|
Oct 05
2020
|
Eric Dobmeier President, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,337
+50.0%
|
-
|
|
Oct 05
2020
|
Tom Frohlich Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
153,398
+50.0%
|
-
|
|
Oct 05
2020
|
Davis Jerel Director |
BUY
Grant, award, or other acquisition
|
Indirect |
7,888,369
+50.0%
|
-
|
|
Oct 05
2020
|
Davis Jerel Director |
BUY
Grant, award, or other acquisition
|
Direct |
730,470
+50.0%
|
-
|
|
Oct 05
2020
|
Srinivas Akkaraju Director |
BUY
Grant, award, or other acquisition
|
Indirect |
3,168,388
+50.0%
|
-
|